Endocrinology, Vol 137, 4363-4371, Copyright © 1996 by Endocrine Society

ARTICLES

Heparin inhibition of insulin-like growth factor-binding protein-3 binding to human fibroblasts and rat glioma cells: role of heparan sulfate proteoglycans

YW Yang, M Yanagishita and MM Rechler
Growth and Development Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

The mitogenic action of insulin-like growth factors (IGFs) on target cells is determined by interaction with signaling IGF-I receptors and modulated by interactions with IGF-binding proteins (IGFBPs). IGFBP-3, an abundant IGFBP that binds IGF-I and IGF-II with high affinity, can form soluble inhibitory complexes with the IGFs that prevent them from binding to IGF-I receptors. Alternatively, IGFBP-3 can bind to the cell surface and possibly potentiate IGF action or act independently of the IGFs. Previous studies showed that heparin inhibited IGFBP-3 binding to the cell surface and increased its accumulation in the medium, suggesting that it might act as a competitive inhibitor of IGFBP-3 binding to structurally similar heparan sulfate proteoglycans on the cell surface. We evaluated this hypothesis by binding 125I-labeled recombinant glycosylated human IGFBP-3 to human fetal skin fibroblasts (GM-10) and to C6 rat glioma cells at 12 C. Heparin inhibited [125I]IGFBP-3 binding more effectively than chondroitin sulfate and dextran sulfate. Complete digestion of cell surface heparan sulfate and chondroitin sulfate glycosaminoglycans using heparitinase and chondroitinase ABC, however, did not significantly decrease IGFBP-3 binding. Quantitative removal was demonstrated by analysis of parallel cultures of cells whose glycosaminoglycans had been biosynthetically labeled using Na2 35SO4. These results suggested that IGFBP-3 did not bind to heparan sulfate glycosaminoglycans on the cell surface, and that the inhibition of IGFBP-3 binding by heparin most likely resulted from its direct interaction with the heparin-binding domains of IGFBP- 3. When [125I]IGFBP-3 was incubated with GM-10 fibroblasts or C6 glioma cells at 37 C for 4 h, only 10% of the bound ligand remained associated with the cell surface; approximately 90% of the cell-associated radio- activity was internalized and could be recovered in lysates of acid- washed cells. Incubation with IGF-I or heparin decreased the total cell- associated radioactivity, but did not affect internalization. These results suggest that direct interaction of heparin or IGF-I with IGFBP- 3 inhibits its ability to bind to the surface of GM-10 fibroblasts and C6 glioma cells.

This article has been cited by other articles:

				G. Zappala, C. Elbi, J. Edwards, J. Gorenstein, M. M. Rechler, and N. Bhattacharyya Induction of Apoptosis in Human Prostate Cancer Cells by Insulin-Like Growth Factor Binding Protein-3 Does Not Require Binding to Retinoid X Receptor-{alpha} Endocrinology, April 1, 2008; 149(4): 1802 - 1812. [Abstract] [Full Text] [PDF]

				N. Bhattacharyya, K. Pechhold, H. Shahjee, G. Zappala, C. Elbi, B. Raaka, M. Wiench, J. Hong, and M. M. Rechler Nonsecreted Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Can Induce Apoptosis in Human Prostate Cancer Cells by IGF-independent Mechanisms without Being Concentrated in the Nucleus J. Biol. Chem., August 25, 2006; 281(34): 24588 - 24601. [Abstract] [Full Text] [PDF]

				P. E. Spoerri, S. Caballero, S. H. Wilson, L. C. Shaw, and M. B. Grant Expression of IGFBP-3 by Human Retinal Endothelial Cell Cultures: IGFBP-3 Involvement in Growth Inhibition and Apoptosis Invest. Ophthalmol. Vis. Sci., January 1, 2003; 44(1): 365 - 369. [Abstract] [Full Text] [PDF]

				S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF]

				J. A. Coverley, J. L. Martin, and R. C. Baxter The Effect of Phosphorylation by Casein Kinase 2 on the Activity of Insulin-Like Growth Factor-Binding Protein-3 Endocrinology, February 1, 2000; 141(2): 564 - 570. [Abstract] [Full Text] [PDF]

				C. Agarwal, A. Lambert, R. A.S. Chandraratna, E. A. Rorke, and R. L. Eckert Vitamin D Regulates Human Ectocervical Epithelial Cell Proliferation and Insulin-Like Growth Factor-Binding Protein-3 Level Biol Reprod, March 1, 1999; 60(3): 567 - 572. [Abstract] [Full Text]

				P. F. Collett-Solberg, S. E. Nunn, T. B. Gibson, and P. Cohen Identification of Novel High Molecular Weight Insulin-Like Growth Factor-Binding Protein-3 Association Proteins in Human Serum J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2843 - 2848. [Abstract] [Full Text]

				S. M. Firth, U. Ganeshprasad, and R. C. Baxter Structural Determinants of Ligand and Cell Surface Binding of Insulin-like Growth Factor-binding Protein-3 J. Biol. Chem., January 30, 1998; 273(5): 2631 - 2638. [Abstract] [Full Text] [PDF]

				P. G. Campbell and D. L. Andress Insulin-like growth factor (IGF)-binding protein-5-(201---218) region regulates hydroxyapatite and IGF-I binding Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E1005 - E1013. [Abstract] [Full Text] [PDF]

				M. M. Rechler Editorial: Growth Inhibition by Insulin-Like Growth Factor (IGF) Binding Protein-3--What's IGF Got To Do with It? Endocrinology, July 1, 1997; 138(7): 2645 - 2647. [Full Text] [PDF]